Forecast Of The Day: Boston Scientific

BSX: Boston Scientific logo
Boston Scientific


Boston Scientific’s (NYSE:BSX) Revenue from Endoscopy declined from around $1.9 billion in 2019 to about $1.8 billion in 2020. However, Trefis expects the number to rise to about $2.2 billion in 2021 and $2.4 billion in 2022. Endoscopy devices are used to diagnose and treat gastrointestinal (GI) and pulmonary conditions, and use less invasive technologies.


Relevant Articles
  1. What To Expect From Boston Scientific Stock Following Q1 Earnings?
  2. This Software Company Is Likely To Offer Better Returns Over Boston Scientific Stock
  3. Company Of The Day: Boston Scientific
  4. Is Boston Scientific Stock A Good Buy At $43?
  5. What To Expect From Boston Scientific Stock Following Q4 Earnings?
  6. Should You Buy Boston Scientific Stock Over Its Industry Peer?

While revenues saw a dip in 2020 due to the Covid-19 pandemic, which resulted in a decline in elective surgeries, we expect sales to pick up from 2021 driven by the introduction of new products and international expansion.

So What?

We think the projected post-Covid growth isn’t fully priced into Boston Scientific’s stock yet. We value the stock at about $50 per share, a premium of about 10% versus the current market price.

See Our Complete Analysis For Boston Scientific

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016

See all Trefis Price Estimates and Download Trefis Data here

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams